Boston-based Biogen Idec plans to use some $2 billion in cash and leverage from its stock to buy new drugs and drug companies, according to a report Monday in a German newspaper. Biogen Idec is particularly interested in buying experimental therapies that are close to marketing approval. This is just the latest sign that the market for biotech drugs has turned red-hot for biotech companies with interesting pipeline prospects.
- here's the report from the Boston Globe
ALSO: Biogen Idec's BG-12 hit its primary endpoint for MS in a Phase II trial. Report